![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
/jornal/2024/08/itausa-itsa4-lucro-liquido-recorrente-de-r-3-64-bilhoes-no-2t24-crescimento-de-22-4/
/jornal/2024/07/itausa-aprova-7a-emissao-de-debentures-no-montante-de-r-1-3-bilhao/
/jornal/2024/07/carteira-recomendada-semanal-com-ranking-carteiras-de-22-a-26-de-julho-de-2024/
/jornal/2024/06/itausa-ira-pagar-r-1-7-bilhao-em-juros-sobre-o-capital-proprio/
/jornal/2024/05/itausa-itsa4-lucro-liquido-recorrente-de-r-3-585-bilhoes-no-1t24-aumento-de-38-1/
/jornal/2024/03/itausa-aprova-pagamento-de-juros-sobre-o-capital-proprio-no-montante-bruto-de-r-723-milhoes/
/jornal/2024/03/itausa-itsa4-lucro-liquido-recorrente-de-r-3-4milhoes-no-4t23-aumento-de-3/
/jornal/2024/03/veja-a-lista-completa-das-empresas-que-pagarao-dividendos-e-jcp-no-mes-de-marco/
/jornal/2024/02/itausa-aprova-pagamento-de-dividendos-e-jcp-no-montante-de-r-5-6-bilhoes/
/jornal/2024/01/confira-os-pagamentos-de-dividendos-e-juros-sobre-capital-proprio-na-primeira-semana-de-janeiro/
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -7.40740740741 | 0.54 | 0.5685 | 0.414 | 42659 | 0.48534021 | CS |
4 | -0.155 | -23.6641221374 | 0.655 | 0.66 | 0.4 | 88709 | 0.53978686 | CS |
12 | -0.59 | -54.128440367 | 1.09 | 1.1885 | 0.4 | 77186 | 0.71883756 | CS |
26 | -1.52 | -75.2475247525 | 2.02 | 2.0438 | 0.4 | 73469 | 1.123887 | CS |
52 | -4.47 | -89.939637827 | 4.97 | 5.1 | 0.4 | 67177 | 1.76428982 | CS |
156 | -39.7 | -98.7562189055 | 40.2 | 46.875 | 0.4 | 323355 | 20.49525554 | CS |
260 | -38.05 | -98.7029831388 | 38.55 | 138.7875 | 0.4 | 758750 | 64.99412043 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions